Co-Founder and CEO


Lorenzo is the Co-Founder & CEO of GreenBone Ortho srl, a startup founded in 2014 to develop a highly innovative wood-derived, biomimetic and re-absorbable bone implants to repair critical defects in load load bearing and non-loaded bones. Lorenzo has a background in Pharmacology and Business in Innovation, with more than 25 years experiences in R&D, Business Development and Venture Capital. He held various senior positions in multinational companies such as Zambon Group SpA and Cardinal Health Inc. General Manager of Zcube srl (Research Venture of Zambon Group) from 2008, Lorenzo established collaborations and investments with major universities hubs in Europe, United States and Israel, as well as with Mission Bay Capital and the California Institute for Quantitative Biosciences (QB3), headquartered on the UCSF Mission Bay campus. Board member of biotech start-ups, including SuppreMol GmbH acquired by Baxter International Inc. in 2015. President of Italy HealthCare Licensing Group (Italy HLG) 2010-2014.

Gitte Pedersen

CEO and Co-Founder

About Gitte Pedersen

Gitte is a scientist/CEO with a mission to cure cancer. Gitte started Genomic Expression together with her brother, Morten, after her parents were diagnosed with cancer. The company got off the ground as the diagnostic partner of a $32M “Genome Denmark” project, and she then raised money to establish an independent lab in Boston. Gitte’s dream team to cure cancer has tons of start-up experience ranging from genomics to commercial launch of drugs. The unpleasant truth is that only one out of four cancer treatments prolong life. To help rectify this, Genomic Expression finds the best drug for the patient and the best patient for the drug by sequencing RNA, which is like the software of the cell, instead of focusing on DNA, which is like the hard disk. RNA analysis can show if a tumor will respond to new immune therapies, which are the only kind of therapies that offer a potential cure. Genomic Expression reinvented the business model to generate revenue while clinically validating its OneRNA™ platform, and has established four funded clinical programs aiming to introduce OneRNA™ into the standard of care. The concept is“test before you treat,” which will disrupt the current standard of care paradigm that treats 75% of patients without providing them with any benefits. Gitte has a degree in chemical engineering and previously worked for Novo Nordisk, which she left to start her own consulting company which advised the Danish government and a number of biotech companies. In this position, she has structured several deals with an aggregate value of +$1B. Gitte has raised +$6.5M in grants for Genomic Expression, closed +$1M in collaboration deals, and put the company into the top 10 of the XTC competition in 2016, at which Gitte was invited to pitch Richard Branson at Necker Island. She has also risen to the top of a number of other pitch competitions, including MedTech Top 50 Innovator 2017, #2in the Women’s Founders Pitch 2016, Top 5 diagnostic companies at the Molecular Tri-Conference 2016, and the Red Herring Top 100 2016.

The Finalists

Innovation Summit &
Award In Oncology

Eleven innovators will compete at the Lyfebulb-Helsinn Investment Fund Innovation Summit for the first ever Lyfebulb-Helsinn Investment Fund Innovation Award, which will be presented to an exceptional innovator with outstanding entrepreneurial potential to commercialize creative efforts and ideas to better manage cancer using drugs, medical devices, or consumer products, and healthcare information technologies


Deadline for applications is January 22, 2018 at 11:59pm EST

Applications Are Now Closed

The Award

One innovator will be awarded the first Lyfebulb-Helsinn Investment Fund Innovation Award in cancer treatment and cancer supportive care

lyfebulb helsinn 2018 - oncology awards


Monetary grants up to $25K will be awarded to the winners, as well as the opportunity for all finalists to be in a position to be better noticed by venture capital funds


National and international recognition. The benefit for innovators of participating is
the visibility given to the selected 10 finalists, and the Winner in particular

Invitation to the Lyfebulb–Helsinn Innovation Summit 2018 in Monaco as one of 10 Finalists.
The Innovation Summit aims to link innovators with senior leadership from Lyfebulb and Helsinn in order
to spotlight innovators’ efforts and ideas, and provide professional discussion, direction, and inspiration.

The winner will be chosen on March 27, 2018 by a prestigious, international panel.


At this Summit, 10 selected Innovators will compete for
monetary grants and be given the opportunity to be considered for a
possible investment by the Helsinn Investment Fund




Beyond presenting their innovative ventures to this group, the 10 finalists will also have a chance to interact and exchange ideas on how to advance further patient innovatorship in the cancer community, engage with Lyfebulb founders, Helsinn Investment Fund leadership, representatives from the patient community, key opinion leaders, and potential investors and compete for a monetary grant.

The Lyfebulb-Helsinn Investment Fund Innovation Summit stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features people who have created a product and a company based on issues encountered because of their personal experiences with a chronic illness.

Patient innovators have a unique ability to create a value-adding disease intervention beyond therapy. Our aim is to support patient-driven innovation and we are laser-focused on improving the quality of life for those living with cancer.


The Award is open to innovators currently working on an
groundbreaking project, which can advance the prevention, management, or
care of cancer. The Award is open to innovators focused on the better
management of cancer using drugs, medical devices, or consumer
products, and healthcare information technologies.


The judging panel will look for evidence of:

  • How does the invention/product have the potential to improve the lives of people with cancer?
  • How is the product or service unique in the market (not an altered marketed product) and meets other demands as well?
  • Usage of innovative and effective technologies that are scalable
  • Ability to meet most of the healthcare challenges (e.g. funding, regulations, requirements for clinical testing, etc.)

The Jury


March 26, 2018: Morning
March 26, 2018: Afternoon
Peer-to-peer meet-ups
March 26, 2018: Evening
Informal dinner
March 27, 2018: Morning
Plenary “pitch” session: presentations
March 27, 2018: Mid-Morning
Standing lunch for participants and jury
March 27, 2018: Afternoon
Afternoon workshops & Plenary session
March 27, 2018: Evening
Gala dinner & Award winner announcement

Driving Change


Lyfebulb is a business focused on bringing innovative products and solutions focused on chronic disease to market. Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease.

Helsinn Investment Fund

The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients

Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions

For more information, visit